Creative Biolabs, as a leading solution provider in the field of antibody development, engineering and products, is working diligently towards discovering the novel therapeutics of cancer by distributing high-standard antibody-drug conjugate products for global customers.
Studies show that ADCs, a family of innovative target medicines that delivers a cytotoxic drug to specific sites using an antibody as a cargo, are a promising treatment of cancer. Normally, an ADC is made up of an antibody, a cytotoxic drug, and a small molecular linker connecting antibody and drug. Creative Biolabs provides standard ADC products that meet all prerequisites for the development of an efficacious ADC, including customized ADCs, drug linker complexes, anti-Ab ADCs, anti-drug Abs, etc.
Various customarily prepared ADCs are available at Creative Biolabs, obtained through conjugating therapeutic antibodies against cancer surface antigens with different drug-linker complexes, and applicable to proof-of-concept, target validation, and control group. The best-sellers are Anti-TNFRSF8 (Brentuximab)-VC-PAB-MMAE ADC, Anti-CD33 (clone hP67.6)-AcBut-Calicheamicin ADC, Anti-ERBB2 (clone 14C)-SMCC-DM1 ADC, etc.
Clean (>95% purity) drug-linker complexes are offered to ease the process of conjugation, conducive to ADC production process, consisting well-established compounds such as MC-vc-PAB-MMAE, and innovative peptide linker-based duocarmycin derivative, which are well-defined with LC-MS and 1HNMR spectroscopy, and suitable for miniature research or large-scale GMP ADC manufacturing.
The list of anti-Ab ADCs are intended for screening ADC-suitable internalizing antibodies under “load-bearing” conditions to ease the process of ADC development, which primarily belong to proteins (either Protein A or Protein G) and secondary antibodies, like IgG (H+L), IgG Fab, and IgG Fc.
ADCs carry high potent toxins, whose pharmacokinetic (PK) properties and safety should be exhaustively tested before entering clinical tests on human. Such properties hinder the process of developing relative antibodies. To resolve this problem, Creative Biolabs offers anti-drug Abs to target ADC toxic antigens, such as MMAE, MMAF, Calicheamicin, Duocarmycin, etc.
Creating an antibody-drug conjugate (ADC) is a process of meticulous investigation, careful design, and sophisticated combination. Creative BioLabs owns comprehensive in-stock ADC products that can help kick-start the ADC projects of global clients and can get delivered instantly to accelerate the progress of ADC development as much as possible. Customers can also get full support for ADC development in a one-stop manner, by the considerate solutions from ADC formulation to clinical evaluation that are based upon the high-end technology platforms.
For in-depth information, please visit https://www.creative-biolabs.com/adc.
About Creative Biolabs
Creative Biolabs is established in 2004, in New York, an expert in advanced antibody biochemistry and engineering. With the practical experience gained after 10 years of exploration in the ADC direction, the company has won recognition in targeted immunotherapy and antibody-drug conjugate (ADC) development globally, through providing comprehensive products and solutions.